Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2020

Open Access 01-12-2020 | Anticoagulant | Research

Health-related quality of life in nonvalvular atrial fibrillation patients with controlled or uncontrolled anticoagulation status

Authors: José Felipe Varona, José Miguel Seguí-Ripoll, Cristina Lozano-Duran, Luis Miguel Cuadrado-Gómez, Juan Bautista Montagud-Moncho, Antonio Ramos-Guerrero, José Carlos Mirete-Ferrer, Esther Donado, Javier García-Alegría, the REQUOL Study Group

Published in: Health and Quality of Life Outcomes | Issue 1/2020

Login to get access

Abstract

Background

There is a dearth of evidence regarding Health-Related Quality of Life (HRQoL) in nonvalvular atrial fibrillation (NVAF) patients undergoing oral anticoagulation therapy. Our objective was to describe HRQoL in NVAF patients on oral anticoagulation, focusing on uncontrolled patients on vitamin K antagonists (VKAs) versus controlled patients on VKAs or non-vitamin K antagonist oral anticoagulants (NOACs), in a real-world setting. Additionally, we assessed the clinical characteristics of patients with uncontrolled anticoagulation.

Methods

An observational, multicentre, and cross-sectional study, enrolling 38 Spanish Hospitals' Internal Medicine Departments. HRQoL was assessed using the validated Spanish version of the Sawicki questionnaire. High self-perceived HRQoL was indicated by high scores in the general treatment satisfaction and self-efficacy dimensions, and by low scores in the strained social network, daily hassles and distress dimensions.

Results

Five hundred and one patients were included for assessment. Mean scores ± SD were closer to a high perceived HRQoL in controlled than uncontrolled patients for the five dimensions of the questionnaire: 4.9 ± 1.0 versus 3.6 ± 1.3 for general treatment satisfaction; 4.3 ± 1.0 versus 3.6 ± 1.0 for self-efficacy, 3.1 ± 0.9 versus 3.9 ± 1.1 for strained social network, 2.1 ± 0.8 versus 3.0 ± 1.0 for daily hassles and 1.8 ± 0.9 versus 2.6 ± 1.2 for distress.

Conclusions

HRQoL in patients with controlled anticoagulant status treated with NOACs or VKAs was better than in patients with uncontrolled anticoagulant status. This seems to indicate that anticoagulation control status influences perception of HRQoL, highlighting the importance of its evaluation when assessing HRQoL in NVAF patients.
Literature
1.
Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–47.
2.
Sankaranarayanan R, Kirkwood G, Visweswariah R, Fox DJ. How does chronic atrial fibrillation influence mortality in the modern treatment era? Curr Cardiol Rev. 2015;11(3):190–8.PubMedPubMedCentral
3.
4.
Batul SA, Gopinathannair R. Atrial fibrillation in heart failure: a therapeutic challenge of our times. Korean Circ J. 2017;47(5):644–62.PubMedPubMedCentral
5.
Freeman JV, Simon DN, Go AS, Spertus J, Fonarow GC, Gersh BJ, et al. Association between atrial fibrillation symptoms, quality of life, and patient outcomes: results from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes. 2015;8(4):393–402.PubMed
6.
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Rev Española Cardiol. 2017;70(1):033.
7.
Kamel H, Okin PM, Elkind MS, Iadecola C. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke. 2016;47(3):895–900.PubMedPubMedCentral
8.
Carmo JFD, Morelato RL, Pinto HP, Oliveira ERAD. Disability after stroke: a systematic review. Fisioter Mov. 2015;28:407–18.
9.
Gomez-Doblas JJ, Muniz J, Martin JJ, Rodriguez-Roca G, Lobos JM, Awamleh P, et al. Prevalence of atrial fibrillation in Spain. OFRECE study results. Rev Española Cardiol. 2014;67(4):259–69.
10.
Johnsen SP, Dalby LW, Täckström T, Olsen J, Fraschke A. Cost of illness of atrial fibrillation: a nationwide study of societal impact. BMC Health Serv Res. 2017;17(1):714.PubMedPubMedCentral
11.
Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda JG, Van Gelder IC. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace. 2011;13(10):1375–85.PubMed
12.
López-López JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ (Clin Res Ed). 2017;359:j5058-j.
13.
Anguita Sanchez M, Bertomeu Martinez V, Cequier FA. Quality of vitamin K antagonist anticoagulation in Spain: prevalence of poor control and associated factors. Rev Española Cardiol. 2015;68(9):761–8.
14.
Reig-Rosello G, Contreras MM, Suarez-Fernandez C, Gonzalez-Hernandez A, Cardona P, Pons-Amate JM, et al. Clinical profile and satisfaction with anticoagulated treatment in patients with non-valvular atrial fibrillation attended in Internal Medicine and Neurology departments of Spain. Rev Neurol. 2017;65(8):361–7.PubMed
15.
Garcia-Sempere A, Hurtado I, Bejarano-Quisoboni D, Rodriguez-Bernal C, Santa-Ana Y, Peiro S, et al. Quality of INR control and switching to non-Vitamin K oral anticoagulants between women and men with atrial fibrillation treated with Vitamin K Antagonists in Spain. A population-based, real-world study. PLoS ONE. 2019;14(2):e0211681.PubMedPubMedCentral
16.
Farmakis D, Davlouros P, Giamouzis G, Giannakoulas G, Pipilis A, Tsivgoulis G, et al. Direct oral anticoagulants in nonvalvular atrial fibrillation: practical considerations on the choice of agent and dosing. Cardiology. 2018;140(2):126–32.PubMed
17.
Ahlsson A, Manolis AS, Casadei B, Van Putte B, Popescu BA, Atar D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.PubMed
18.
Mani H, Lindhoff-Last E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des Dev Ther. 2014;8:789–98.
19.
Benzimra M, Bonnamour B, Duracinsky M, Lalanne C, Aubert JP, Chassany O, et al. Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation. Patient Prefer Adher. 2018;12:79–877.
20.
Monz BU, Connolly SJ, Korhonen M, Noack H, Pooley J. Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study. Int J Cardiol. 2013;168(3):2540–7.PubMed
21.
Alegret JM, Vinolas X, Arias MA, Martinez-Rubio A, Rebollo P, Rafols C, et al. New oral anticoagulants versus vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation. Int J Med Sci. 2014;11(7):680–4.PubMedPubMedCentral
22.
Balci KG, Balci MM, Canpolat U, Sen F, Akboga MK, Suleymanoglu M, et al. Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation. Anatol J Cardiol. 2016;16(7):474–81.PubMed
23.
López-Sendón J, Merino JL. Poor anticoagulation control in atrial fibrillation: how much longer? Rev Española Cardiol (Engl Ed). 2015;68(09):740–2.
24.
Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S, et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2012;126(19):2309–16.PubMed
25.
Hasan SS, Teh KM, Ahmed SI, Chong DW, Ong HC, Naina B. Quality of life (QoL) and international normalized ratio (INR) control of patients attending anticoagulation clinics. Public Health. 2015;129(7):954–62.PubMed
26.
Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–9.PubMed
27.
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey. Chest. 2010;138(5):1093–100.PubMed
28.
Sánchez González R, Yanes Baonza M, Cabrera Majada A, Ferrer García-Borrás JM, Álvarez Nido R, Barrera LE. Adaptación transcultural de un cuestionario para medir la calidad de vida de los pacientes con anticoagulación oral. Aten Primaria. 2004;34(7):353–9.PubMedPubMedCentral
29.
Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. J Am Med Assoc. 1999;281(2):145–50.
30.
Siebenhofer A, Hemkens LG, Rakovac I, Spat S, Didjurgeit U. Self-management of oral anticoagulation in elderly patients—effects on treatment-related quality of life. Thromb Res. 2012;130(3):1.
31.
Marquez-Contreras E, Martell-Claros N, Gil-Guillen V, De la Figuera-Von WM, Sanchez-Lopez E, Gil-Gil I, et al. Quality of life with rivaroxaban in patients with non-valvular atrial fibrilation by therapeutic compliance. Qual Life Res. 2017;26(3):647–54.PubMed
32.
Anguita M, Marín F, Roldán I, Cequier A, Bertomeu V, Muñiz J. Satisfaction with medical care in patients with atrial fibrillation treated with vitamin K antagonists versus new oral anticoagulants. Rev Española Cardiol (Engl Ed). 2015;68(06):537–9.
33.
Fareau S, Baumstarck K, Chiche L, Farcet A, Molines C, Auquier P, et al. Évaluation de la qualité de vie des patients âgés en fibrillation atriale sous anticoagulants au long cours : antivitamine K versus Anticoagulants oraux directs. La Revue Méd Interne. 2015;36:A175–A176176.
34.
Bartoli-Abdou JK, Patel JP, Xie R, Dzahini O, Vadher B, Brown A, et al. Associations between illness beliefs, medication beliefs, anticoagulation-related quality of life, and INR control: Insights from the Switching Study. Res Pract Thromb Haemost. 2018;2(3):497–507.PubMedPubMedCentral
35.
Barrios V, Escobar C, Prieto L, Osorio G, Polo J, Lobos JM, et al. Anticoagulation control in patients with nonvalvular atrial fibrillation attended at primary care centers in Spain: The PAULA study. Rev Española Cardiol. 2015;68(9):769–76.
36.
Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest. 2013;144(5):1555–633.PubMed
37.
Randolph TC, Simon DN, Thomas L, Allen LA, Fonarow GC, Gersh BJ, et al. Patient factors associated with quality of life in atrial fibrillation. Am Heart J. 2016;182:135–43.PubMedPubMedCentral
38.
Abohelaika S, Wynne H, Avery P, Robinson B, Kesteven P, Kamali F. Impact of age on long-term anticoagulation and how gender and monitoring setting affect it: implications for decision making and patient management. Br J Clin Pharmacol. 2016;82(4):1076–83.PubMedPubMedCentral
39.
Maeder MT, Konig T, Bogdanovic S, Schneider I, Eugster W, Ammann P, et al. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation—real-life data from a survey in Eastern Switzerland. Swiss Med Weekly. 2017;6(147):w14503.
40.
Morillas P, Pallarés V, Llisterri JL, Sanchis C, Sánchez T, Fácila L, et al. Prevalencia de fibrilación auricular y uso de fármacos antitrombóticos en el paciente hipertenso ≥ 65 años. El registro FAPRES. Rev Española Cardiol. 2010;63(08):943–50.
41.
Hwang J, Han S, Bae HJ, Jun SW, Choi SW, Lee CH, et al. NOAC adherence of patients with atrial fibrillation in the real world: dosing frequency matters? Thromb Haemost. 2020;120(2):306–13.PubMed
42.
Ozaki AF, Choi AS, Le QT, Ko DT, Han JK, Park SS, et al. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2020;13(3):e005969.PubMed
43.
Piran S, Delaney J, Schulman S, Salib M, Panju M, Pai M. Direct oral anticoagulants in the real world: insights into appropriate prescribing and medication use. Can J Nurs Res. 2017;49(3):105–7.PubMed
Metadata
Title
Health-related quality of life in nonvalvular atrial fibrillation patients with controlled or uncontrolled anticoagulation status
Authors
José Felipe Varona
José Miguel Seguí-Ripoll
Cristina Lozano-Duran
Luis Miguel Cuadrado-Gómez
Juan Bautista Montagud-Moncho
Antonio Ramos-Guerrero
José Carlos Mirete-Ferrer
Esther Donado
Javier García-Alegría
the REQUOL Study Group
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2020
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-020-01563-1

Other articles of this Issue 1/2020

Health and Quality of Life Outcomes 1/2020 Go to the issue

Research

A biopsychosocial-cultural model for understanding oral-health-related quality of life among adolescent orthodontic patients

Research

Regression-based normative data for social health scale for the elderly (short version) in eastern China

Research

Health-related quality of life and scar satisfaction in a cohort of children operated on for sacrococcygeal teratoma

Research

Psychometric properties of the Japanese version of the Kansas City Cardiomyopathy Questionnaire in Japanese patients with chronic heart failure

Correction

Correction to: Relationship of objectively measured physical activity and sedentary behaviour with health-related quality of life among breast cancer survivors

Research

Health-related quality of life (FACT-GP) in Sweden